Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given a consensus rating of “Hold” by the twelve ratings firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $5.2188.

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Tuesday, October 14th. Royal Bank Of Canada reduced their price target on Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Tuesday, August 12th.

Maravai LifeSciences Trading Down 5.4%

NASDAQ:MRVI opened at $3.30 on Monday. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $8.53. The stock’s 50-day moving average is $2.76 and its two-hundred day moving average is $2.41. The stock has a market cap of $842.69 million, a PE ratio of -2.43 and a beta of 0.33.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors have recently made changes to their positions in the company. Ethic Inc. lifted its holdings in shares of Maravai LifeSciences by 62.8% during the 3rd quarter. Ethic Inc. now owns 16,951 shares of the company’s stock valued at $49,000 after buying an additional 6,540 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Maravai LifeSciences by 141.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 18,757 shares of the company’s stock valued at $54,000 after buying an additional 10,982 shares during the last quarter. Orion Porfolio Solutions LLC lifted its holdings in shares of Maravai LifeSciences by 34.5% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 321,879 shares of the company’s stock valued at $776,000 after buying an additional 82,522 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Maravai LifeSciences by 121.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock valued at $43,000 after buying an additional 9,870 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its holdings in shares of Maravai LifeSciences by 3.1% during the 2nd quarter. Lazard Asset Management LLC now owns 1,450,421 shares of the company’s stock valued at $3,495,000 after buying an additional 44,128 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.